Compounded tirzepatide vs Zepbound

Zepbound has been through the FDA. A compounded version of tirzepatide has not. And unlike semaglutide, there is no study at all comparing the two, so anyone telling you they perform the same is not working from evidence.

What Zepbound has that a compounded version does not

Trial evidence. Tirzepatide's obesity programme produced some of the largest average weight loss results in the drug class, and the FDA reviewed that evidence before approving it.

Manufacturing oversight. The approved product is made under federal manufacturing rules the FDA inspects against.

A tested dose schedule delivered in a pre-filled pen with fixed settings, rather than a vial you draw from.

A known formulation. You know exactly what is in it, at what strength, every time.

Where the two clocks diverged

Compounding tirzepatide at scale was permitted because Zepbound and Mounjaro were in shortage. The FDA determined that shortage was resolved on 19 December 2024, and enforcement discretion ended 18 February 2025 for state licensed pharmacies and 19 March 2025 for outsourcing facilities.

That was about two months before the equivalent semaglutide deadlines. On 1 May 2026 the FDA proposed removing tirzepatide from the list of bulk substances outsourcing facilities may compound from entirely, on the basis that there is no clinical need. Comments closed 29 June 2026.

The evidence gap is bigger here

For semaglutide there is one real world comparison, and it found compounded slightly behind on average and further behind at the higher weight loss thresholds.

For tirzepatide there is nothing. No trial, no cohort comparison, no published outcome data. Every number you have seen about how well tirzepatide works comes from studies of the approved product.

This is worth being blunt about, because tirzepatide's trial results are the reason many people choose it over semaglutide in the first place. Those results belong to Zepbound and Mounjaro. They do not automatically transfer to a compounded copy.

The price argument changed in 2026

Cost has been the main reason to choose compounded. Two things happened.

Medicare. CMS launched the Medicare GLP-1 Bridge, a time limited demonstration running from 1 July 2026 to 31 December 2027, giving eligible Part D beneficiaries certain GLP-1 drugs for fifty dollars a month. Zepbound KwikPen is one of the named products. There is fine print worth knowing: the Part D deductible does not apply, the fifty dollars does not count toward your true out of pocket total, and there is no low income subsidy attached.

Cash prices. The approved products became available at substantially reduced cash prices through a federal direct purchasing channel launched in early 2026.

Neither route fits everyone. But if you chose compounded on price a year ago, the arithmetic is different now and it is worth redoing before your next refill.

What has not changed

Tirzepatide is an effective molecule and compounded versions have helped people lose weight. Nothing here says otherwise, and nothing here is a reason to stop something a clinician prescribed you without talking to them.

The claim we would push back on is that the two products are interchangeable. One has been examined and one has not, and for tirzepatide specifically there is not even a comparison to argue about.

What to ask

• Is this Zepbound or Mounjaro, or a compounded tirzepatide?
• Which facility compounds it and are they registered with the FDA?
• Does my titration match the approved schedule?
• Am I eligible for the Medicare GLP-1 Bridge, and have I checked?
• What would the approved product cost me now through insurance or a federal channel?

Sources

• FDA, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize"
• FDA, "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List"; Federal Register document 2026-08552
• Centers for Medicare and Medicaid Services, Medicare GLP-1 Bridge
• Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022. doi:10.1056/nejmoa2206038
• Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine, 2025. doi:10.1056/NEJMoa2416394

How we verify: see /how-we-verify.

Keep reading

What the FDA has documented about compounded tirzepatide, at /guides/is-compounded-tirzepatide-safe.

What compounded GLP-1s cost and why they were cheaper, at /guides/compounded-glp1-cost.